NEWS & PERSPECTIVE
Semaglutide gains FDA approval for treating obesity in adolescents aged ≥12 years
Semaglutide, a glucagon-like peptide-1 (GLP-1) analog that aids in weight loss by suppressing appetite, has recently gained approval from the United States (US) Food and Drug Administration (FDA) to treat obesity in children aged ≥12 years.
By 2030, obesity is expected to affect more than 250 million children and adolescents aged 5-19 years worldwide, making it a global health challenge.
STEP TEENS was a randomized, double-blind placebo-controlled, parallel-group, multinational phase 3a trial conducted between October 2019 and March 2022 at 37 locations.
At week 68, the mean percentage change in BMI was -16.1% in the semaglutide arm vs. 0.6% in the placebo arm (estimated difference=-16.7%; 95% CI: -20.3 to -13.2; p<0.001).
The rates of adverse events (AEs) were similar in the placebo group (82%) and the semaglutide group (79%).
In conclusion, when combined with lifestyle changes, the recently approved once-weekly subcutaneous semaglutide significantly reduces BMI in adolescents with obesity, providing an effective treatment option for this population who fail to achieve optimal weight control with lifestyle intervention alone.
Comparing the newly FDA-approved tirzepatide with insulin glargine in T2DM patients at high CV risk: The SURPASS-4 trial
Tirzepatide was approved by the U.S. Food and Drug Administration (FDA) on May 13, 2022 as the first and only dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist for type 2 diabetes mellitus (T2DM), given its potent glucose-lowering effects.1
Preventative statin therapy reduces AHF and mortality in patients with ACS as the first manifestation of ASCVD
Mixed data have been observed on the role of statins in the preventative setting of cardiovascular disease (CVD).1 However, Dr. Raffaele Bugiardini, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Italy and his colleagues conducted a recent study published in the Journal of the American College of Cardiology, which demonstrated evidence that receiving statin therapy before initial acute coronary syndrome (ACS) could reduce acute heart failure (AHF) and improve patient survival rates.2
Latest guideline addresses the gap in managing adult stage 1 hypertension with a low 10-year ASCVD risk
The 2017 Hypertension Clinical Practice Guideline issued by the American College of Cardiology/American Heart Association (ACC/AHA) Task Force outlined the general blood pressure (BP) management approach to adults with stage 1 hypertension and a 10-year risk for atherosclerotic cardiovascular diseas
Lipoprotein(a) as a novel therapeutic target lowering the risk of cardiovascular disease
Lipoprotein(a) (Lp(a)) is a unique lipoprotein that has emerged as an independent risk factor for vascular diseases.1 In the general population, the plasma levels of Lp(a) are similar in men and women and are skewed with a tail towards the highest levels (Figure 1).2
Combination antiplatelet and anticoagulation therapy to bring positive outcomes in diabetes and cardiovascular disease
More recently, a strategy of dual pathway antithrombotic therapy with antiplatelet and a reduced dose of anticoagulant has been tested and shown to be effective. The COMPASS trial demonstrated that aspirin plus rivaroxaban 2.5mg twice daily was superior to placebo for the reduction of ischemic event
Rheumatoid arthritis is associated with an increased risk of heart failure
The burden of heart failure (HF) is increasing worldwide.1 Cardiovascular disease (CVD) risk scores have identified rheumatoid arthritis (RA) patients to be at higher risk of developing HF.2
A case review on cardiac risk stratification in the secondary prevention of cardiovascular diseases
Cardiac risk stratification is an assessment used to evaluate a patient's risk of developing cardiovascular disease (CVD) or the risk of a cardiac event occurring in noncardiac surgeries. CVDs are the number one cause of death
Widening and persistent educational inequality among women with physician-diagnosed hypertension in Hong Kong
Hypertension is the leading global preventable risk factor for cardiovascular disease and premature death.1 In 2025, the estimated global prevalence of hypertension will be 29%.2 In Hong Kong, around 27% of the population suffers from hypertension, with around half being unaware of their